EQ earnings

Treatment with itolizumab did not improve complete or overall response rates at Day 29 Itolizumab achieved statistical significance in multiple secondary endpoints demonstrating compelling clinical benefit in longer-term outcomes, including complete response at Day 99, duration of complete response and failure-free survival Breakthrough Therapy designation and meeting requests to discuss potential for Accelerated Approval submitted to FDA, feedback expected during May 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics

Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2 ulcerative colitis study recently completed; topline data expected Q1 2025 Management will host a conference call and webcast today at 8:30 am ET Equillium Inc. (NASDAQ:EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equillium's rights to itolizumab

Equillium grants Ono an option to purchase rights to itolizumab Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments Ono to fund Equillium's continued research and development of itolizumab during the exercise period Conference call and webcast today at 8:30 a.m. ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, and Ono Pharmaceutical Co., Ltd. ("Ono"), today announced an option and asset purchase agreement through which Ono gains the exclusive option to

Itolizumab demonstrates clinically meaningful response in highly proteinuric subjects: 5 of 6 (83%) subjects achieved complete or partial response and 4 of 6 (67%) subjects achieved > 80% reduction in urine protein creatinine ratio (UPCR) by week 28 8 of 12 (67%) subjects achieved > 50% reduction in UPCR (6 subjects still dosing) Itolizumab continues to demonstrate favorable safety and tolerability through six months of treatment Management will host a conference call and webcast today at 8:00 am ET Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical ne

Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

Acquisition includes two first-in-class clinical-stage assets and proprietary product discovery platform Creates a robust immunology pipeline with significant value-creating milestones, and provides a strong clinical and research team with complementary expertise in immuno-inflammatory diseases Closing consideration of 5,699,492 shares of common stock of Equillium Equillium to host a conference call and webcast today at 8:00 a.m. Eastern Time Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutic